乐复能对克罗恩病的免疫调节作用及临床疗效

Immunomodulatory effects and clinical efficacy of novaferon in the treatment of Crohn's disease

目的观察乐复能对克罗恩病的临床疗效以及免疫调节作用。方法收集2013年1月至2015年3月黄石市中心医院消化内科诊治的克罗恩病患者76例,使用数字法随机分为观察组和对照组,每组38例。流式细胞仪检测Th17和Treg细胞;ELISA法检测IL-17、IL-10和IL-6的表达;比较两组患者的临床疗效、复发率和不良反应。结果两组患者治疗前Th17和Treg细胞比例以及IL-17、IL-10、IL-6表达水平比较差异无统计学意义(P>0.05),治疗后观察组在Th17细胞、IL-17和IL-6的降低方面以及Treg和IL-10的升高方面优于对照组(P<0.05)。观察组临床治疗有效率为92.1%,显著高于对照组的73.7%(P<0.05)。观察组复发率为7.9%,显著低于对照组的23.7%(P<0.05)。观察组临床不良反应发生率为10.5%,显著低于对照组的31.6%(P<0.05)。结论乐复能可以改善克罗恩病患者Th17、Treg细胞以及IL-17、IL-10因子失衡,临床疗效显著,使用安全,具有一定的临床应用价值。

Objective To observe the immunomodulatory effects of novaferon on patients with Crohn＇s disease and its clinical efficacy.Methods Seventy-six patients with Crohn＇s disease in Huangshi Central Hospital from January 2013 to March 2015 were randomly divided into observation group（n=38） and control group（n=38）.The Th17 and Treg cells were detected by cytometry.The expression of IL-17,IL-10 and IL-6 was detected by ELISA.The clinical effect,recurrence rate and adverse reactions of the two groups were compared.Results Before treatment,there was no significant difference in Th17 and Treg cells ratio,or the expression of IL-17,IL-10 and IL-6（P〉 0.05）.After treatment,the levels of Th17 cells,IL-17 and IL-6 in observation group were higher than those of control group with lower levels of Treg cells and IL-10（P〈0.05）.The clinic effective rate of observation group was higher than that of control group（92.1%vs.73.7%,P〈 0.05）.The recurrence rate in observation group was lower than that of control group（7.9%vs.23.7%,P〈0.05）.The adverse reactions rate of observation group was lower than that of control group（10.5%vs.31.6%,P〈 0.05）.Conclusion Novaferon can regulate Th17/Treg and improve IL-17/IL-10 immune balance,with significant clinical efficacy and safety in treating patients with Crohn＇s disease.